Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Shares Sold by Driehaus Capital Management LLC

Driehaus Capital Management LLC lessened its stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) by 0.7% during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 556,835 shares of the company’s stock after selling 3,695 shares during the period. Driehaus Capital Management LLC owned 0.95% of Protagonist Therapeutics worth $19,294,000 as of its most recent SEC filing.

Several other institutional investors have also recently added to or reduced their stakes in PTGX. Millennium Management LLC increased its position in Protagonist Therapeutics by 2,135.6% in the 2nd quarter. Millennium Management LLC now owns 958,283 shares of the company’s stock valued at $33,205,000 after acquiring an additional 915,418 shares during the period. Superstring Capital Management LP purchased a new stake in Protagonist Therapeutics in the 4th quarter valued at approximately $8,694,000. Renaissance Technologies LLC boosted its holdings in Protagonist Therapeutics by 813.4% in the 2nd quarter. Renaissance Technologies LLC now owns 297,467 shares of the company’s stock valued at $10,307,000 after purchasing an additional 264,900 shares in the last quarter. ADAR1 Capital Management LLC purchased a new stake in Protagonist Therapeutics in the 4th quarter valued at approximately $4,606,000. Finally, Kynam Capital Management LP boosted its holdings in Protagonist Therapeutics by 10.2% in the 4th quarter. Kynam Capital Management LP now owns 2,004,875 shares of the company’s stock valued at $45,972,000 after purchasing an additional 186,218 shares in the last quarter. Institutional investors and hedge funds own 98.63% of the company’s stock.

Protagonist Therapeutics Price Performance

Shares of NASDAQ:PTGX opened at $44.56 on Friday. The business’s 50 day simple moving average is $41.76 and its 200-day simple moving average is $34.23. The firm has a market capitalization of $2.62 billion, a price-to-earnings ratio of 18.26 and a beta of 2.17. Protagonist Therapeutics, Inc. has a 12 month low of $13.72 and a 12 month high of $48.00.

Protagonist Therapeutics (NASDAQ:PTGX) last issued its quarterly earnings data on Tuesday, August 6th. The company reported ($0.50) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.50). The company had revenue of $4.17 million for the quarter, compared to analyst estimates of $40.00 million. On average, equities analysts anticipate that Protagonist Therapeutics, Inc. will post 2.31 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on the company. BTIG Research lifted their price objective on Protagonist Therapeutics from $41.00 to $51.00 and gave the company a “buy” rating in a report on Wednesday, July 24th. HC Wainwright lifted their price objective on Protagonist Therapeutics from $40.00 to $50.00 and gave the company a “buy” rating in a report on Thursday, September 12th. JMP Securities lowered their price objective on Protagonist Therapeutics from $45.00 to $43.00 and set a “market outperform” rating on the stock in a report on Wednesday, August 7th. TD Cowen raised Protagonist Therapeutics to a “strong-buy” rating in a report on Wednesday. Finally, StockNews.com raised Protagonist Therapeutics from a “hold” rating to a “buy” rating in a research note on Thursday, August 8th. Seven analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $49.86.

Insider Buying and Selling

In related news, CFO Asif Ali sold 14,203 shares of Protagonist Therapeutics stock in a transaction that occurred on Wednesday, September 11th. The stock was sold at an average price of $44.49, for a total transaction of $631,891.47. Following the completion of the transaction, the chief financial officer now directly owns 34,960 shares in the company, valued at approximately $1,555,370.40. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In related news, Director William D. Waddill sold 8,000 shares of Protagonist Therapeutics stock in a transaction that occurred on Tuesday, September 10th. The stock was sold at an average price of $45.00, for a total transaction of $360,000.00. Following the completion of the transaction, the director now directly owns 12,000 shares in the company, valued at approximately $540,000. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Asif Ali sold 14,203 shares of the business’s stock in a transaction on Wednesday, September 11th. The shares were sold at an average price of $44.49, for a total value of $631,891.47. Following the completion of the transaction, the chief financial officer now owns 34,960 shares of the company’s stock, valued at $1,555,370.40. The disclosure for this sale can be found here. Insiders sold 30,203 shares of company stock worth $1,311,891 in the last ninety days. Insiders own 5.40% of the company’s stock.

About Protagonist Therapeutics

Protagonist Therapeutics, Inc, a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis.